Search
olodaterol (Striverdi Respimat)
Indications:
- chronic obstructive pulmonary disease
- chronic bronchitis
- pulmonary emphysema
Contraindications:
- acute COPD exacerbation
- asthma exacerbation
- acute bronchospasm
Dosage:
- inhalation spray as a once-daily
Adverse effects:
- paradoxical bronchospasm
- nasopharyngitis
- upper respiratory tract infection
- bronchitis
- cough
- urinary tract infection
- dizziness
- rash
- diarrhea
- back pain
- arthralgia
- boxed warning highlighting:
- increased risk for asthma-related death
Mechanism of action:
- long-acting beta-adrenergic agonist
Interactions
drug adverse effects of adrenergic receptor agonists
General
long-acting beta adrenergic receptor agonist (LABA)
inhalation agent (inhalant)
References
- FDA News Release. July 31, 2014
FDA approves Striverdi Respimat to treat chronic obstructive
pulmonary disease.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407465.htm
Component-of
olodaterol/tiotropium (Stiolto Respimat)